Specifically, in the estrogen receptor-α (ERα) expressing (ER+) breast cancer cells (MCF-7), Ca2+ entry via Orai3 targets the proto-oncogenic transcription factor c-myc via the MAPK (originally named ERK) pathway to trigger cell proliferation arrest [126], contributing to ER+ breast tumorigenesis [127]. Here, ORAI3 is linked to breast carcinoma.